Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAGO study of atorvastatin added to intravenous glucocorticoids for active moderate-to-severe Graves' orbitopathy in hypercholesterolemic patients
2018-001317-33Phase 2Completed
- Sponsor
- Azienda Ospedaliero-Universitaria Pisana
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of atorvastatin in Graves' ophthalmopathy (TED) (2 arms), sponsored by Azienda Ospedaliero-Universitaria Pisana. Primary endpoint: Response rate of Graves' orbitopathy at 24 weeks. Started Oct 2020; status: completed.
02
Drugs
atorvastatin
03
Conditions
Graves' ophthalmopathy (TED)
Beyond the preview
Go deeper on 2018-001317-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001317-33.